KP 607
Alternative Names: KP-607Latest Information Update: 24 Jan 2022
Price :
$50 *
At a glance
- Originator Kaken Pharmaceutical
- Class Anti-infectives; Antifungals; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Onychomycosis
Most Recent Events
- 10 Dec 2021 Kaken Pharmaceutical completes a phase II clinical trial in Onychomycosis in Japan (Topical) (JapicCTI205299)
- 08 Sep 2018 Kaken Pharmaceutical plans a phase I trial for Onychomycosis in Japan (Topical) in September 2018 (JapicCTI184101)
- 01 Sep 2018 Phase-I clinical trials in Onychomycosis in Japan (Topical)(JapicCTI184101)